Takashi Yamane
Takashi Yamane has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Ayaka Inoue
Department of Rheumatology, Kakogawa Central City Hospital
7 shared publicationsAkira Hashiramoto
Department of Biophysics, Kobe University Graduate School of Health Sciences
6 shared publications- Masahiro Nishida
National Institute of Advanced Industrial Science and Technology
6 shared publications Noriaki Yasuda
Department of Rheumatology, Kakogawa Central City Hospital
6 shared publications- Osamu Maruyama
National Institute of Advanced Industrial Science and Technology
6 shared publications Takahisa Ohnishi
Department of Rheumatology, Kakogawa Central City Hospital
5 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1975875
Glucocorticoid discontinuation and hepatic safety during avacopan treatment for antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study at a single center in Japan
Introduction: Real-world data on glucocorticoid discontinuation and liver enzyme abnormalities during avacopan treatment remain limited, particularly in patients who initiate treatment later in the disease course. Methods: We retrospectively studied 52 patients with microscopic polyangiitis or granulomatosis with polyangiitis who initiated avacopan at a single center in Japan. Glucocorticoid discontinuation was evaluated in 40 patients receiving systemic glucocorticoids at initiation, while liver enzyme abnormalities were assessed in all 52 patients. Time to glucocorticoid discontinuation was analyzed using Kaplan-Meier methods and Cox proportional hazards regression. Baseline factors associated with liver enzyme abnormalities were examined using univariable logistic regression. Results: Glucocorticoid discontinuation during avacopan treatment was observed in 27 patients (68%), with a median time of 196 days (95% confidence interval, 37–355 days). Longer disease duration before avacopan initiation was associated with a lower rate of glucocorticoid discontinuation after adjustment for baseline prednisolone dose and disease activity (hazard ratio per year, 0.86; 95% confidence interval, 0.76-0.97; p = 0.017). Relapse occurred in five patients. Liver enzyme abnormalities during avacopan treatment were observed in 26 patients (50%). Treatment modification due to liver enzyme abnormalities was required in eight patients. Three permanently discontinued avacopan, four continued treatment after dose reduction, and one resumed treatment at a reduced dose after temporary interruption. Liver enzyme levels normalized in seven patients, while normalization was not assessed in one. Reduced-dose initiation was not significantly associated with liver enzyme abnormalities. Discussion: In this Japanese single-center cohort, glucocorticoid discontinuation during avacopan treatment was observed in 27 of 40 patients, and a shorter disease duration before avacopan initiation was associated with more rapid discontinuation. Liver enzyme abnormalities were frequent and sometimes required treatment modification. These findings describe treatment patterns and clinical outcomes in routine practice but do not establish the efficacy, hepatic safety, or overall benefit-risk profile of avacopan.
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1975875
Open AccessGlucocorticoid discontinuation and hepatic safety during avacopan treatment for antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study at a single center in Japan
Introduction: Real-world data on glucocorticoid discontinuation and liver enzyme abnormalities during avacopan treatment remain limited, particularly in patients who initiate treatment later in the disease course. Methods: We retrospectively studied 52 patients with microscopic polyangiitis or granulomatosis with polyangiitis who initiated avacopan at a single center in Japan. Glucocorticoid discontinuation was evaluated in 40 patients receiving systemic glucocorticoids at initiation, while liver enzyme abnormalities were assessed in all 52 patients. Time to glucocorticoid discontinuation was analyzed using Kaplan-Meier methods and Cox proportional hazards regression. Baseline factors associated with liver enzyme abnormalities were examined using univariable logistic regression. Results: Glucocorticoid discontinuation during avacopan treatment was observed in 27 patients (68%), with a median time of 196 days (95% confidence interval, 37–355 days). Longer disease duration before avacopan initiation was associated with a lower rate of glucocorticoid discontinuation after adjustment for baseline prednisolone dose and disease activity (hazard ratio per year, 0.86; 95% confidence interval, 0.76-0.97; p = 0.017). Relapse occurred in five patients. Liver enzyme abnormalities during avacopan treatment were observed in 26 patients (50%). Treatment modification due to liver enzyme abnormalities was required in eight patients. Three permanently discontinued avacopan, four continued treatment after dose reduction, and one resumed treatment at a reduced dose after temporary interruption. Liver enzyme levels normalized in seven patients, while normalization was not assessed in one. Reduced-dose initiation was not significantly associated with liver enzyme abnormalities. Discussion: In this Japanese single-center cohort, glucocorticoid discontinuation during avacopan treatment was observed in 27 of 40 patients, and a shorter disease duration before avacopan initiation was associated with more rapid discontinuation. Liver enzyme abnormalities were frequent and sometimes required treatment modification. These findings describe treatment patterns and clinical outcomes in routine practice but do not establish the efficacy, hepatic safety, or overall benefit-risk profile of avacopan.
- Open Access
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1983345
Glucocorticoid dose at 26 weeks and subsequent relapse in anti-ARS antibody-positive antisynthetase syndrome under concomitant immunosuppressive therapy: a retrospective cohort study
Background: Glucocorticoids (GCs) remain central to antisynthetase syndrome (ASSD) treatment, but relapse during tapering and GC-related adverse effects remain important concerns. Because GC-related morbidity may emerge early, minimizing GC exposure while maintaining disease control is important. Whether the GC dose during early tapering is associated with subsequent relapse remains unclear. We investigated whether a GC dose of ≤5 mg/day at approximately 6 months was associated with subsequent relapse in anti-aminoacyl-tRNA synthetase (ARS) antibody-positive ASSD receiving concomitant immunosuppressive therapy. Methods: We retrospectively analyzed 45 patients with anti-ARS antibody-positive ASSD treated with systemic GCs and concomitant immunosuppressive therapy. We performed a week-26 landmark analysis, representing approximately 6 months after treatment initiation, among patients who remained relapse-free and under observation through the landmark. Subsequent relapse-free survival was compared between patients receiving GC ≤5 and >5 mg/day in prednisolone equivalents at the landmark. Results: During overall follow-up, 26 of 45 patients (58%) experienced relapse, whereas only 4 (8.9%) relapsed before week 26. Among 41 patients who remained relapse-free and under observation through the landmark, 17 were receiving GC ≤5 mg/day and 24 were receiving >5 mg/day. During post-landmark follow-up, 22 patients experienced subsequent relapse. Patients receiving GC ≤5 mg/day at week 26 had higher subsequent relapse-free survival than those receiving >5 mg/day (log-rank p = 0.007). In multivariable analyses, GC ≤5 mg/day at week 26 was associated with a lower risk of subsequent relapse after adjustment for Raynaud phenomenon and initial GC dose (HR 0.27, 95% CI 0.08–0.86; p = 0.027) and after adjustment for Raynaud phenomenon and anti-Jo-1 positivity (HR 0.32, 95% CI 0.10–0.99; p = 0.047). Conclusion: Among patients with anti-ARS antibody-positive ASSD receiving concomitant immunosuppressive therapy who remained relapse-free and under observation through the week-26 landmark, a GC dose ≤5 mg/day was associated with a lower risk of subsequent relapse. Although these findings should not be generalized to all patients or interpreted as establishing an optimal tapering target, the GC dose at this landmark may serve as a clinically useful marker of early disease control or treatment response. Prospective studies are warranted to validate its clinical significance.
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1983345
Open AccessGlucocorticoid dose at 26 weeks and subsequent relapse in anti-ARS antibody-positive antisynthetase syndrome under concomitant immunosuppressive therapy: a retrospective cohort study
Background: Glucocorticoids (GCs) remain central to antisynthetase syndrome (ASSD) treatment, but relapse during tapering and GC-related adverse effects remain important concerns. Because GC-related morbidity may emerge early, minimizing GC exposure while maintaining disease control is important. Whether the GC dose during early tapering is associated with subsequent relapse remains unclear. We investigated whether a GC dose of ≤5 mg/day at approximately 6 months was associated with subsequent relapse in anti-aminoacyl-tRNA synthetase (ARS) antibody-positive ASSD receiving concomitant immunosuppressive therapy. Methods: We retrospectively analyzed 45 patients with anti-ARS antibody-positive ASSD treated with systemic GCs and concomitant immunosuppressive therapy. We performed a week-26 landmark analysis, representing approximately 6 months after treatment initiation, among patients who remained relapse-free and under observation through the landmark. Subsequent relapse-free survival was compared between patients receiving GC ≤5 and >5 mg/day in prednisolone equivalents at the landmark. Results: During overall follow-up, 26 of 45 patients (58%) experienced relapse, whereas only 4 (8.9%) relapsed before week 26. Among 41 patients who remained relapse-free and under observation through the landmark, 17 were receiving GC ≤5 mg/day and 24 were receiving >5 mg/day. During post-landmark follow-up, 22 patients experienced subsequent relapse. Patients receiving GC ≤5 mg/day at week 26 had higher subsequent relapse-free survival than those receiving >5 mg/day (log-rank p = 0.007). In multivariable analyses, GC ≤5 mg/day at week 26 was associated with a lower risk of subsequent relapse after adjustment for Raynaud phenomenon and initial GC dose (HR 0.27, 95% CI 0.08–0.86; p = 0.027) and after adjustment for Raynaud phenomenon and anti-Jo-1 positivity (HR 0.32, 95% CI 0.10–0.99; p = 0.047). Conclusion: Among patients with anti-ARS antibody-positive ASSD receiving concomitant immunosuppressive therapy who remained relapse-free and under observation through the week-26 landmark, a GC dose ≤5 mg/day was associated with a lower risk of subsequent relapse. Although these findings should not be generalized to all patients or interpreted as establishing an optimal tapering target, the GC dose at this landmark may serve as a clinically useful marker of early disease control or treatment response. Prospective studies are warranted to validate its clinical significance.
- Open Access
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (41) , e51085
Secondary pulmonary alveolar proteinosis mimicking progression of interstitial lung disease during treatment for adult-onset still’s disease
Rationale: Secondary pulmonary alveolar proteinosis (sPAP) is a rare disorder caused by impaired surfactant clearance due to alveolar macrophage dysfunction and is often associated with hematologic disorders or immunosuppressive therapy. In patients with connective tissue disease–associated interstitial lung disease (CTD-ILD), worsening respiratory findings are frequently interpreted as progression of the underlying ILD, which may delay recognition of sPAP, particularly when anti–granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies are negative. In the present case, preexisting ILD and repeated bronchoscopic findings of organizing pneumonia further obscured the development of sPAP, making the diagnosis particularly challenging. Patient concerns: A 68-year-old woman with adult-onset Still’s disease (AOSD)–associated ILD developed progressive respiratory deterioration during immunosuppressive therapy. Despite apparent control of AOSD-related systemic inflammation, serum Krebs von den Lungen-6 (KL-6) levels increased markedly, and new diffuse ground-glass opacities appeared on chest computed tomography. Diagnoses: Repeated bronchoscopic examinations demonstrated organizing pneumonia without features suggestive of PAP, supporting the interpretation of progressive CTD-ILD. However, KL-6 levels progressively increased to 19,333 IU per liter despite treatment, raising suspicion of PAP. Anti–GM-CSF antibody testing was negative, and a definitive diagnosis could not be established during life. Autopsy ultimately revealed sPAP with periodic acid–Schiff–positive intra-alveolar material and myelodysplastic syndrome (MDS). Hematologic abnormalities had initially been attributed to systemic inflammation, and subsequent bone marrow examination showed MDS-like dysplasia without establishing a definitive diagnosis of MDS. Interventions: The patient received escalating immunosuppressive therapies, including a Janus kinase inhibitor, under the assumption of progressive CTD-ILD, with the aim of minimizing glucocorticoid exposure. Outcomes: Respiratory failure progressed despite treatment, and bronchoscopy was not feasible in the terminal stage. The patient died of respiratory failure. Postmortem examination confirmed sPAP and MDS. Lessons: In patients with CTD-ILD receiving immunosuppressive therapy, marked and progressive elevation of KL-6 should prompt reconsideration of the diagnosis, even when bronchoscopy does not demonstrate PAP and anti–GM-CSF antibodies are negative. Early recognition is essential to avoid inappropriate intensification of immunosuppression and further impairment of alveolar macrophage function.
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105  (41) , e51085
Open AccessSecondary pulmonary alveolar proteinosis mimicking progression of interstitial lung disease during treatment for adult-onset still’s disease
Rationale: Secondary pulmonary alveolar proteinosis (sPAP) is a rare disorder caused by impaired surfactant clearance due to alveolar macrophage dysfunction and is often associated with hematologic disorders or immunosuppressive therapy. In patients with connective tissue disease–associated interstitial lung disease (CTD-ILD), worsening respiratory findings are frequently interpreted as progression of the underlying ILD, which may delay recognition of sPAP, particularly when anti–granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies are negative. In the present case, preexisting ILD and repeated bronchoscopic findings of organizing pneumonia further obscured the development of sPAP, making the diagnosis particularly challenging. Patient concerns: A 68-year-old woman with adult-onset Still’s disease (AOSD)–associated ILD developed progressive respiratory deterioration during immunosuppressive therapy. Despite apparent control of AOSD-related systemic inflammation, serum Krebs von den Lungen-6 (KL-6) levels increased markedly, and new diffuse ground-glass opacities appeared on chest computed tomography. Diagnoses: Repeated bronchoscopic examinations demonstrated organizing pneumonia without features suggestive of PAP, supporting the interpretation of progressive CTD-ILD. However, KL-6 levels progressively increased to 19,333 IU per liter despite treatment, raising suspicion of PAP. Anti–GM-CSF antibody testing was negative, and a definitive diagnosis could not be established during life. Autopsy ultimately revealed sPAP with periodic acid–Schiff–positive intra-alveolar material and myelodysplastic syndrome (MDS). Hematologic abnormalities had initially been attributed to systemic inflammation, and subsequent bone marrow examination showed MDS-like dysplasia without establishing a definitive diagnosis of MDS. Interventions: The patient received escalating immunosuppressive therapies, including a Janus kinase inhibitor, under the assumption of progressive CTD-ILD, with the aim of minimizing glucocorticoid exposure. Outcomes: Respiratory failure progressed despite treatment, and bronchoscopy was not feasible in the terminal stage. The patient died of respiratory failure. Postmortem examination confirmed sPAP and MDS. Lessons: In patients with CTD-ILD receiving immunosuppressive therapy, marked and progressive elevation of KL-6 should prompt reconsideration of the diagnosis, even when bronchoscopy does not demonstrate PAP and anti–GM-CSF antibodies are negative. Early recognition is essential to avoid inappropriate intensification of immunosuppression and further impairment of alveolar macrophage function.
- 6 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45  (8) , 4833-4843
Real-world retention of nintedanib and factors associated with treatment discontinuation in connective tissue disease–associated interstitial lung disease: a retrospective cohort study of 92 patients
Introduction/Objectives Treatment discontinuation of nintedanib is an important clinical issue in patients with connective tissue disease–associated interstitial lung disease (CTD-ILD). This study aimed to evaluate real-world retention of nintedanib across CTD subtypes and to explore factors associated with treatment discontinuation. Methods We conducted a single-center retrospective study of consecutive patients with CTD-ILD who initiated nintedanib between June 2019 and December 2024. Clinical data, including baseline characteristics, concomitant therapies, and treatment outcomes, were collected. The primary outcome was the 48-week retention rate. Kaplan–Meier analysis and Cox proportional hazards models were used to evaluate factors associated with treatment discontinuation. Results A total of 92 patients were included (rheumatoid arthritis [RA], n = 25; idiopathic inflammatory myopathy [IIM], n = 25; systemic sclerosis [SSc], n = 21; microscopic polyangiitis [MPA], n = 10; Sjögren disease [SjD], n = 9). The 48-week retention rate was 82.6%, with a median treatment duration of 978 days (IQR, 586–1356). Retention was lowest in RA, with higher rates observed in other CTD subtypes. Stratified analyses showed that this difference was evident in patients aged < 65 years (p = 0.001) and those receiving an initial dose of 300 mg/day (p = 0.003), but not in older patients or those receiving < 300 mg/day. In univariable analysis, RA (HR 3.10, p = 0.024) and an initial dose of 300 mg/day (HR 2.67, p = 0.050) were associated with discontinuation. However, RA was not independently associated with discontinuation after adjustment for age and initial dose in the exploratory multivariable analysis. Conclusions Nintedanib showed favorable retention in CTD-ILD. Although retention appeared lower in RA, this difference may be influenced by patient characteristics such as age and initial dosing. Individualized dose selection and appropriate management of adverse events may improve treatment persistence. Key Points • Nintedanib showed favorable 48-week retention in patients with CTD-ILD in a real-world setting. • Lower retention observed in RA was influenced by age and initial dosing, rather than disease subtype alone.
- 6 July 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45  (8) , 4833-4843
Real-world retention of nintedanib and factors associated with treatment discontinuation in connective tissue disease–associated interstitial lung disease: a retrospective cohort study of 92 patients
Introduction/Objectives Treatment discontinuation of nintedanib is an important clinical issue in patients with connective tissue disease–associated interstitial lung disease (CTD-ILD). This study aimed to evaluate real-world retention of nintedanib across CTD subtypes and to explore factors associated with treatment discontinuation. Methods We conducted a single-center retrospective study of consecutive patients with CTD-ILD who initiated nintedanib between June 2019 and December 2024. Clinical data, including baseline characteristics, concomitant therapies, and treatment outcomes, were collected. The primary outcome was the 48-week retention rate. Kaplan–Meier analysis and Cox proportional hazards models were used to evaluate factors associated with treatment discontinuation. Results A total of 92 patients were included (rheumatoid arthritis [RA], n = 25; idiopathic inflammatory myopathy [IIM], n = 25; systemic sclerosis [SSc], n = 21; microscopic polyangiitis [MPA], n = 10; Sjögren disease [SjD], n = 9). The 48-week retention rate was 82.6%, with a median treatment duration of 978 days (IQR, 586–1356). Retention was lowest in RA, with higher rates observed in other CTD subtypes. Stratified analyses showed that this difference was evident in patients aged < 65 years (p = 0.001) and those receiving an initial dose of 300 mg/day (p = 0.003), but not in older patients or those receiving < 300 mg/day. In univariable analysis, RA (HR 3.10, p = 0.024) and an initial dose of 300 mg/day (HR 2.67, p = 0.050) were associated with discontinuation. However, RA was not independently associated with discontinuation after adjustment for age and initial dose in the exploratory multivariable analysis. Conclusions Nintedanib showed favorable retention in CTD-ILD. Although retention appeared lower in RA, this difference may be influenced by patient characteristics such as age and initial dosing. Individualized dose selection and appropriate management of adverse events may improve treatment persistence. Key Points • Nintedanib showed favorable 48-week retention in patients with CTD-ILD in a real-world setting. • Lower retention observed in RA was influenced by age and initial dosing, rather than disease subtype alone.
- 29 June 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 10  (2)
Benralizumab for eosinophilic granulomatosis with polyangiitis and subclinical cardiac involvement: A fertility-preserving case report
Cardiac involvement, which may remain clinically silent, is a major determinant of prognosis in eosinophilic granulomatosis with polyangiitis, and remission induction generally requires glucocorticoids (GCs) combined with cyclophosphamide or rituximab. In contrast, treatment selection may be challenging in women wishing to preserve fertility because cyclophosphamide carries a risk of gonadal toxicity. We report the case of a 40-year-old woman with a history of asthma, eosinophilic chronic rhinosinusitis, and eosinophilic otitis media who developed postpartum-onset eosinophilic granulomatosis with polyangiitis and presented with neurological and cutaneous manifestations. Elevated cardiac troponin I levels and newly developed electrocardiographic abnormalities suggested subclinical myocardial injury despite the absence of cardiac symptoms. Intravenous methylprednisolone pulse therapy was initiated immediately. Because cardiac troponin I levels showed no early decline after GC initiation, and GC monotherapy was considered potentially insufficient to control eosinophil-mediated myocardial injury, additional eosinophil-targeted therapy was selected after shared decision-making that balanced fertility preservation with the need for prompt disease control. Benralizumab was chosen because of its potent eosinophil-depleting effect. Peripheral eosinophils rapidly decreased to zero, troponin I normalised by Day 26, and GCs were successfully discontinued within 5 months. To our knowledge, this is the first report of benralizumab used as part of a fertility-preserving remission-induction strategy to avoid cyclophosphamide in a woman with eosinophilic granulomatosis with polyangiitis and cardiac involvement. This approach may represent an individualised therapeutic option for carefully selected patients in whom fertility preservation is an important treatment consideration.
- 29 June 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 10  (2)
Benralizumab for eosinophilic granulomatosis with polyangiitis and subclinical cardiac involvement: A fertility-preserving case report
Cardiac involvement, which may remain clinically silent, is a major determinant of prognosis in eosinophilic granulomatosis with polyangiitis, and remission induction generally requires glucocorticoids (GCs) combined with cyclophosphamide or rituximab. In contrast, treatment selection may be challenging in women wishing to preserve fertility because cyclophosphamide carries a risk of gonadal toxicity. We report the case of a 40-year-old woman with a history of asthma, eosinophilic chronic rhinosinusitis, and eosinophilic otitis media who developed postpartum-onset eosinophilic granulomatosis with polyangiitis and presented with neurological and cutaneous manifestations. Elevated cardiac troponin I levels and newly developed electrocardiographic abnormalities suggested subclinical myocardial injury despite the absence of cardiac symptoms. Intravenous methylprednisolone pulse therapy was initiated immediately. Because cardiac troponin I levels showed no early decline after GC initiation, and GC monotherapy was considered potentially insufficient to control eosinophil-mediated myocardial injury, additional eosinophil-targeted therapy was selected after shared decision-making that balanced fertility preservation with the need for prompt disease control. Benralizumab was chosen because of its potent eosinophil-depleting effect. Peripheral eosinophils rapidly decreased to zero, troponin I normalised by Day 26, and GCs were successfully discontinued within 5 months. To our knowledge, this is the first report of benralizumab used as part of a fertility-preserving remission-induction strategy to avoid cyclophosphamide in a woman with eosinophilic granulomatosis with polyangiitis and cardiac involvement. This approach may represent an individualised therapeutic option for carefully selected patients in whom fertility preservation is an important treatment consideration.
- Open Access
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1848854
Glucocorticoid discontinuation in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: associations with tapering patterns and initiation timing
Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) requires prolonged glucocorticoid (GC) therapy in many patients, leading to substantial treatment-related morbidity. Although accumulating evidence has demonstrated the GC-sparing effects of mepolizumab (MPZ) and increasing numbers of patients achieving GC reduction or discontinuation, the patterns of GC tapering and discontinuation, including the influence of MPZ initiation timing, remain unclear. Materials and methods: We conducted a retrospective cohort study of EGPA patients treated with MPZ at a single center in Japan. We evaluated time to GC discontinuation and temporal changes according to MPZ initiation year. The interval from GC initiation to MPZ initiation was also assessed. Early GC discontinuation was defined as GC-free status within 500 days based on the observed temporal distribution of events. Time-to-event outcomes were analyzed using Kaplan–Meier and Cox regression, and early GC-free status was assessed using logistic regression. Results: Thirty-six patients were included. During a median follow-up of 4.6 years, GC discontinuation was achieved in 31 patients (86.1%), including 20 (55.6%) who achieved early GC-free status. The median time from MPZ initiation to GC discontinuation was 452 days. Higher eosinophil counts at MPZ initiation were independently associated with GC discontinuation (HR 1.45, 95% CI 1.08–1.96), whereas the interval from GC initiation to MPZ initiation was not. MPZ initiation in more recent years was associated with earlier GC discontinuation (OR 6.00, 95% CI 1.54–23.44), reflecting faster GC tapering after MPZ initiation. Vasculitis Damage Index (VDI) increased in 4 patients (11.1%) and was infrequent among those achieving early GC-free status. Conclusions: GC discontinuation was achieved in a high proportion of EGPA patients treated with MPZ. Accelerated GC tapering after MPZ initiation was associated with shorter GC treatment duration without an apparent increase in organ damage.
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1848854
Open AccessGlucocorticoid discontinuation in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: associations with tapering patterns and initiation timing
Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) requires prolonged glucocorticoid (GC) therapy in many patients, leading to substantial treatment-related morbidity. Although accumulating evidence has demonstrated the GC-sparing effects of mepolizumab (MPZ) and increasing numbers of patients achieving GC reduction or discontinuation, the patterns of GC tapering and discontinuation, including the influence of MPZ initiation timing, remain unclear. Materials and methods: We conducted a retrospective cohort study of EGPA patients treated with MPZ at a single center in Japan. We evaluated time to GC discontinuation and temporal changes according to MPZ initiation year. The interval from GC initiation to MPZ initiation was also assessed. Early GC discontinuation was defined as GC-free status within 500 days based on the observed temporal distribution of events. Time-to-event outcomes were analyzed using Kaplan–Meier and Cox regression, and early GC-free status was assessed using logistic regression. Results: Thirty-six patients were included. During a median follow-up of 4.6 years, GC discontinuation was achieved in 31 patients (86.1%), including 20 (55.6%) who achieved early GC-free status. The median time from MPZ initiation to GC discontinuation was 452 days. Higher eosinophil counts at MPZ initiation were independently associated with GC discontinuation (HR 1.45, 95% CI 1.08–1.96), whereas the interval from GC initiation to MPZ initiation was not. MPZ initiation in more recent years was associated with earlier GC discontinuation (OR 6.00, 95% CI 1.54–23.44), reflecting faster GC tapering after MPZ initiation. Vasculitis Damage Index (VDI) increased in 4 patients (11.1%) and was infrequent among those achieving early GC-free status. Conclusions: GC discontinuation was achieved in a high proportion of EGPA patients treated with MPZ. Accelerated GC tapering after MPZ initiation was associated with shorter GC treatment duration without an apparent increase in organ damage.
- Open Access
- 19 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1797242
Glucocorticoid reduction with baricitinib in rheumatoid arthritis refractory to prior therapies: a 24-week real-world analysis
Introduction: In a real-world cohort of rheumatoid arthritis (RA) patients who were unable to discontinue glucocorticoids (GCs) despite prior therapies, we aimed to evaluate the GC-sparing effect of baricitinib (BARI) and to identify clinical factors associated with GC reduction. Materials and methods: This single-center retrospective observational study included RA patients who initiated BARI while receiving systemic GCs between 2018 and 2024. Disease activity and daily GC dose were assessed at baseline and at weeks 4, 12, and 24. The primary outcome was the percent reduction in daily GC dose at week 24. Linear and logistic regression analyses were performed to identify factors associated with GC reduction and discontinuation, with two-variable multivariable models constructed to avoid overfitting. Results: Among 177 patients who initiated BARI, 39 (22%) were receiving GCs at treatment initiation and were included in the analysis. After prior exposure to biologic or targeted synthetic DMARDs in 31 patients (79%), 34 (87%) had moderate or higher disease activity by the Clinical Disease Activity Index at baseline, and 27 (69%) had comorbid interstitial lung disease. The median daily GC dose decreased from 3.0 mg/day at baseline to 1.0 mg/day at week 24 ( P < 0.001), with a significant reduction observed as early as week 4. The median GC reduction rate at week 24 was 66%, with 18 of 39 patients (46%) achieving a ≥ 50% reduction and 10 patients (26%) discontinuing GCs entirely. Disease activity improved significantly, with 62% of patients achieving remission or low disease activity by week 24. In linear regression analysis, refractoriness to ≥ 2 prior biologic or targeted synthetic DMARDs was independently associated with a smaller degree of GC reduction. No unexpected safety signals were observed. Conclusion: In this real-world cohort of GC-dependent RA patients with persistent disease activity and frequent ILD comorbidity despite prior therapies, BARI enabled clinically meaningful GC reduction and improved disease activity within 24 weeks. Resistance to multiple prior b/tsDMARDs emerged as a key barrier to GC tapering, highlighting the importance of introducing JAK inhibitors before progression to a difficult-to-treat state.
- 19 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1797242
Open AccessGlucocorticoid reduction with baricitinib in rheumatoid arthritis refractory to prior therapies: a 24-week real-world analysis
Introduction: In a real-world cohort of rheumatoid arthritis (RA) patients who were unable to discontinue glucocorticoids (GCs) despite prior therapies, we aimed to evaluate the GC-sparing effect of baricitinib (BARI) and to identify clinical factors associated with GC reduction. Materials and methods: This single-center retrospective observational study included RA patients who initiated BARI while receiving systemic GCs between 2018 and 2024. Disease activity and daily GC dose were assessed at baseline and at weeks 4, 12, and 24. The primary outcome was the percent reduction in daily GC dose at week 24. Linear and logistic regression analyses were performed to identify factors associated with GC reduction and discontinuation, with two-variable multivariable models constructed to avoid overfitting. Results: Among 177 patients who initiated BARI, 39 (22%) were receiving GCs at treatment initiation and were included in the analysis. After prior exposure to biologic or targeted synthetic DMARDs in 31 patients (79%), 34 (87%) had moderate or higher disease activity by the Clinical Disease Activity Index at baseline, and 27 (69%) had comorbid interstitial lung disease. The median daily GC dose decreased from 3.0 mg/day at baseline to 1.0 mg/day at week 24 ( P < 0.001), with a significant reduction observed as early as week 4. The median GC reduction rate at week 24 was 66%, with 18 of 39 patients (46%) achieving a ≥ 50% reduction and 10 patients (26%) discontinuing GCs entirely. Disease activity improved significantly, with 62% of patients achieving remission or low disease activity by week 24. In linear regression analysis, refractoriness to ≥ 2 prior biologic or targeted synthetic DMARDs was independently associated with a smaller degree of GC reduction. No unexpected safety signals were observed. Conclusion: In this real-world cohort of GC-dependent RA patients with persistent disease activity and frequent ILD comorbidity despite prior therapies, BARI enabled clinically meaningful GC reduction and improved disease activity within 24 weeks. Resistance to multiple prior b/tsDMARDs emerged as a key barrier to GC tapering, highlighting the importance of introducing JAK inhibitors before progression to a difficult-to-treat state.
- 2 December 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45  (1) , 579-586
Glucocorticoid-free remission with simultaneous mepolizumab and rituximab in life-threatening PR3-ANCA-positive eosinophilic granulomatosis with polyangiitis: a case report and literature review
Patients with features of multiple systemic vasculitides are rare but do exist and can be diagnostically challenging. In particular, it can be difficult to distinguish granulomatosis with polyangiitis (GPA) with eosinophilia, proteinase 3 (PR3)-ANCA–positive eosinophilic granulomatosis with polyangiitis (EGPA), and overlap of GPA and EGPA in clinical practice. Nevertheless, in severe cases, rapid therapeutic decisions are required. We report such a life-threatening case of PR3-ANCA–positive vasculitis with eosinophilia, refractory to conventional therapy, that achieved remission with simultaneous biologic therapy using mepolizumab (MPZ) and rituximab (RTX) and provide a case-based review of the efficacy and safety of this dual biologic therapy. An 18-year-old man presented with cough, hemoptysis, leg purpura, and marked eosinophilia (4575/μL). Chest CT revealed alveolar hemorrhage (DAH). Proteinase 3 (PR3)–anti-neutrophil cytoplasmic antibody (ANCA) was positive, and skin biopsy showed leukocytoclastic vasculitis with eosinophil infiltration, consistent with EGPA. He was refractory to methylprednisolone (mPSL) pulse therapy and intravenous cyclophosphamide (IVCY), and DAH worsened, requiring non-invasive ventilation. Plasma exchange, MPZ (300 mg), and RTX (375 mg/m2 weekly × 4) were administered. DAH resolved rapidly after MPZ administration. Eosinophils dropped to 0/μL, but PR3-ANCA remained positive, and thereafter, nephritis developed. At 3 months after disease onset, renal biopsy showed pauci-immune crescentic glomerulonephritis with little eosinophil infiltration. Additional mPSL pulses induced remission, which was maintained with MPZ and RTX. PR3-ANCA turned negative, and proteinuria resolved within 12 months. Glucocorticoids (GCs) were discontinued after 2.5 years, with a Vascular Damage Index (VDI) of 0. No serious infections or adverse events occurred. Although the development of glomerulonephritis after normalization of eosinophil count and DAH remission suggested possible EGPA–GPA overlap, the absence of granulomatous features and the potential phenotypic shift under anti–IL-5 therapy supported a final diagnosis of PR3-ANCA–positive EGPA. In life-threatening situations, the priority should be to initiate agents effective across both entities rather than to delay treatment until classification is certain. Our review suggests that simultaneous biologic therapy with MPZ and RTX can be effective with minimal adverse events and should be considered without hesitation in such critical cases.
- 2 December 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45  (1) , 579-586
Glucocorticoid-free remission with simultaneous mepolizumab and rituximab in life-threatening PR3-ANCA-positive eosinophilic granulomatosis with polyangiitis: a case report and literature review
Patients with features of multiple systemic vasculitides are rare but do exist and can be diagnostically challenging. In particular, it can be difficult to distinguish granulomatosis with polyangiitis (GPA) with eosinophilia, proteinase 3 (PR3)-ANCA–positive eosinophilic granulomatosis with polyangiitis (EGPA), and overlap of GPA and EGPA in clinical practice. Nevertheless, in severe cases, rapid therapeutic decisions are required. We report such a life-threatening case of PR3-ANCA–positive vasculitis with eosinophilia, refractory to conventional therapy, that achieved remission with simultaneous biologic therapy using mepolizumab (MPZ) and rituximab (RTX) and provide a case-based review of the efficacy and safety of this dual biologic therapy. An 18-year-old man presented with cough, hemoptysis, leg purpura, and marked eosinophilia (4575/μL). Chest CT revealed alveolar hemorrhage (DAH). Proteinase 3 (PR3)–anti-neutrophil cytoplasmic antibody (ANCA) was positive, and skin biopsy showed leukocytoclastic vasculitis with eosinophil infiltration, consistent with EGPA. He was refractory to methylprednisolone (mPSL) pulse therapy and intravenous cyclophosphamide (IVCY), and DAH worsened, requiring non-invasive ventilation. Plasma exchange, MPZ (300 mg), and RTX (375 mg/m2 weekly × 4) were administered. DAH resolved rapidly after MPZ administration. Eosinophils dropped to 0/μL, but PR3-ANCA remained positive, and thereafter, nephritis developed. At 3 months after disease onset, renal biopsy showed pauci-immune crescentic glomerulonephritis with little eosinophil infiltration. Additional mPSL pulses induced remission, which was maintained with MPZ and RTX. PR3-ANCA turned negative, and proteinuria resolved within 12 months. Glucocorticoids (GCs) were discontinued after 2.5 years, with a Vascular Damage Index (VDI) of 0. No serious infections or adverse events occurred. Although the development of glomerulonephritis after normalization of eosinophil count and DAH remission suggested possible EGPA–GPA overlap, the absence of granulomatous features and the potential phenotypic shift under anti–IL-5 therapy supported a final diagnosis of PR3-ANCA–positive EGPA. In life-threatening situations, the priority should be to initiate agents effective across both entities rather than to delay treatment until classification is certain. Our review suggests that simultaneous biologic therapy with MPZ and RTX can be effective with minimal adverse events and should be considered without hesitation in such critical cases.
- Open Access
- 15 November 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64  (22) , 3306-3310
Escherichia coli Sternoclavicular Septic Arthritis Secondary to Colon Cancer-associated Bacteremia
Non-traumatic sternoclavicular arthritis is typically caused by either degeneration or non-infectious inflammatory conditions, although septic arthritis can often occur due to Staphylococcus aureus, particularly in immunocompromised individuals. We herein present a case of Escherichia coli (E.coli)-induced sternoclavicular arthritis in a Japanese woman with no underlying disease. As no common source of E. coli bacteremia was identified, colonoscopy revealed early-stage rectal cancer. To our knowledge, this is the first report of septic sternoclavicular arthritis in which colorectal cancer was identified as the source of infection. Clinicians should consider colorectal cancer when septic arthritis caused by gut bacteria is diagnosed without a clear source.
- 15 November 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64  (22) , 3306-3310
Open AccessEscherichia coli Sternoclavicular Septic Arthritis Secondary to Colon Cancer-associated Bacteremia
Non-traumatic sternoclavicular arthritis is typically caused by either degeneration or non-infectious inflammatory conditions, although septic arthritis can often occur due to Staphylococcus aureus, particularly in immunocompromised individuals. We herein present a case of Escherichia coli (E.coli)-induced sternoclavicular arthritis in a Japanese woman with no underlying disease. As no common source of E. coli bacteremia was identified, colonoscopy revealed early-stage rectal cancer. To our knowledge, this is the first report of septic sternoclavicular arthritis in which colorectal cancer was identified as the source of infection. Clinicians should consider colorectal cancer when septic arthritis caused by gut bacteria is diagnosed without a clear source.
- Open Access
- 1 May 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64  (9) , 1423-1426
Solo Addition of Mepolizumab Turned Antineutrophil Cytoplasmic Antibody Negative and Achieved Glucocorticoid Discontinuation in a Patient with Eosinophilic Granulomatosis with Polyangiitis
The IL-5 inhibitor mepolizumab is beneficial in eosinophilic granulomatosis with polyangiitis (EGPA), and the inhibition of antineutrophil cytoplasmic antibody (ANCA) production has been suggested as a possible mechanism. We herein report a 78-year-old Japanese man with EGPA who received solo mepolizumab 300 mg twice for elevated ANCA levels, which led to subsequent GC discontinuation after achieving remission. The patient was able to be freed from the adverse events associated with long-term GC treatment, and the sole addition of mepolizumab also proved that mildly elevated ANCA could be converted to a negative result, thus leading to GC discontinuation.
- 1 May 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64  (9) , 1423-1426
Open AccessSolo Addition of Mepolizumab Turned Antineutrophil Cytoplasmic Antibody Negative and Achieved Glucocorticoid Discontinuation in a Patient with Eosinophilic Granulomatosis with Polyangiitis
The IL-5 inhibitor mepolizumab is beneficial in eosinophilic granulomatosis with polyangiitis (EGPA), and the inhibition of antineutrophil cytoplasmic antibody (ANCA) production has been suggested as a possible mechanism. We herein report a 78-year-old Japanese man with EGPA who received solo mepolizumab 300 mg twice for elevated ANCA levels, which led to subsequent GC discontinuation after achieving remission. The patient was able to be freed from the adverse events associated with long-term GC treatment, and the sole addition of mepolizumab also proved that mildly elevated ANCA could be converted to a negative result, thus leading to GC discontinuation.